Objectives: Cross-linked Hyaluronic Acid hydrogels have proven to be excellent fillers for the volumetric augmentation of soft tissues.
The advanced crosslinking technologies have allowed high rheological levels to allow the use of in several anatomical areas with more resistance to degradation of the implant. In recent years, some have studied new types of cross-linkers to enhance the rheological features of the hydrogel.
Materials / method: For the determination of cell viability and cytotoxicity of NEAUVIA hydrogels MTT test, NRU test and Kenacid Blue test have been performed.
To evaluate the morphological evidences following pegyleted filler treatment in human skin histological and immunohistochemical studies have been performed.
To optimize clinical outcomes, we promote both needle and techniques.
Results: No alterations in cell morphology and viability were detected, which shows of complete biosafety. On the basis of our histological observations, the filler used in this study is safe, and shows no sign of stimulation of the immune system and/or any other adverse reactions.
Conclusion: A new PEG crosslinked HA filler is now available. The aim of our communication will be to explain in vivo and in vitro research on the new molecule in order to provide documentary evidence of its safety and efficacy in the aesthetic and clinic correction of soft tissues. We will also show the clinical technique of Neauvia gel implants.
利益冲突声明
您有否接受任何资金来支持研究这个主题？
否
您是否接受过关于这项研究的任何酬金或其他报酬？
否
你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: Consultant
你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
